Alternatively, since combination therapies may provide synergistic effects and better tumor control, we are currently investigating the potential of combining TAT with 213Bi-anti-hPD-L1 mAb and adoptive transfer of tumor-specific T-cells in the same preclinical human melanoma model. Here, CD274 is linked to melanoma.